Oncoinvent ASA Income Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Operating Revenue	2.73	0.06	0.07
Other Revenue	5.37	5.73	6.22
Revenue	8.1	5.79	6.28
Revenue Growth (YoY)	39.95%	-7.85%	-
Gross Profit	8.1	5.79	6.28
Selling, General & Admin	51.44	55.74	47.34
Other Operating Expenses	83.13	86.22	61.57
Operating Expenses	149.12	153.22	116.89
Operating Income	-141.02	-147.43	-110.61
Interest Expense	-0.08	-0.01	-0.01
Interest & Investment Income	1.34	4.41	4.44
Currency Exchange Gain (Loss)	-0.45	-0.6	-0.11
Pretax Income	-140.2	-143.62	-106.28
Net Income	-140.2	-143.62	-106.28
Net Income to Common	-140.2	-143.62	-106.28
Shares Outstanding (Basic)	92	19	19
Shares Outstanding (Diluted)	92	19	19
Shares Change (YoY)	374.39%	0.27%	-
EPS (Basic)	-1.52	-7.39	-5.48
EPS (Diluted)	-1.52	-7.39	-5.48
Free Cash Flow	-89.75	-164.94	-93.17
Free Cash Flow Per Share	-0.97	-8.48	-4.80
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-1740.31%	-2546.20%	-1760.48%
Profit Margin	-1730.24%	-2480.50%	-1691.55%
Free Cash Flow Margin	-1107.55%	-2848.72%	-1482.94%
EBITDA	-131.81	-139.84	-105.82
D&A For EBITDA	9.2	7.59	4.79
EBIT	-141.02	-147.43	-110.61
Revenue as Reported	8.1	5.79	6.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.